Stage
No active trials
Next date
None yet
Trials
0 active
1 in total
Targets
—
None known yet
What this is
- How it works
- How it works isn't classified yet
- Tested for
- Painful Diabetic Neuropathy
- Main trialPhase 1
- “A Phase 1b study to evaluate the safety, tolerability and pharmacokinetics of multiple ascending doses of CNTX-6016 in healthy subjects and a single cohort to evaluate painful diabetic neuropathy.”In the company’s words, NCT04857957 on ClinicalTrials.gov
Other drugs for Painful Diabetic Neuropathy
- Pregabalin XRBrainfarma Industria Química e Farmacêutica S/A · Phase 3
- BIOxHEALApplied Biologics, LLC · Phase 3
- Amniotic Tissue AllograftBardia Anvar · Phase 3
- ENERGI-F703Energenesis Biomedical Co., Ltd. · Phase 3
- Xianglei Tangzu GaoOneness Biotech Co., Ltd. · Phase 2/3
- Nu-3 gelLakewood-Amedex Inc · Phase 2
Coming up0
No dates coming up.
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials1
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 1Completed | 30 Aug 2023 | Safety, Tolerability & Pharmacokinetics Study of CNTX-6016 in Healthy Subjects and Subjects With PDN |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026